Diagnostic and Grading Accuracy of F-FDOPA PET and PET/CT in Patients with Gliomas: a Systematic Review and Meta-analysis

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2019 Aug 7

PMID 31382920

Citations 18

Authors

Jiarui Xiao

Yizi Jin

Ji Nie

Fukun Chen

Xuelei Ma

Affiliations

Soon will be listed here.

Abstract

Background: Positron emission tomography (PET) and PET/computed tomography (PET/CT) imaging with 3,4-dihydroxy-6-[F] fluoro-L-phenylalanine (F-FDOPA) has been used in the evaluation of gliomas. We performed a meta-analysis to obtain the diagnostic and grading accuracy of F-FDOPA PET and PET/CT in patients with gliomas.

Methods: PubMed, Embase, Cochrane Library and Web of Science were searched through 13 May 2019. We included studies reporting the diagnostic performance of F-FDOPA PET or PET/CT in glioma patients. Pooled sensitivity, specificity, and area under the summary receiver operating characteristic (SROC) curve were calculated from eligible studies on a per-lesion basis.

Results: Eventually, 19 studies were included. Across 13 studies (370 patients) for glioma diagnosis, the pooled sensitivity and specificity of F-FDOPA PET and PET/CT were 0.90 (95%CI: 0.86-0.93) and 0.75 (95%CI: 0.65-0.83). Across 7 studies (219 patients) for glioma grading, F-FDOPA PET and PET/CT showed a pooled sensitivity of 0.88 (95%CI: 0.81-0.93) and a pooled specificity of 0.73 (95%CI: 0.64-0.81).

Conclusions: F-FDOPA PET and PET/CT demonstrated good performance for diagnosing gliomas and differentiating high-grade gliomas (HGGs) from low-grade gliomas (LGGs). Further studies implementing standardized PET protocols and investigating the grading parameters are needed.

Citing Articles

LAT1-specific PET radiotracers: Development and clinical experiences of a new class of cancer-specific radiopharmaceuticals.

Achmad A, Hanaoka H, Holik H, Endo K, Tsushima Y, Kartamihardja A Theranostics. 2025; 15(5):1864-1878.

PMID: 39897549 PMC: 11780518. DOI: 10.7150/thno.99490.

Translation of PET radiotracers for cancer imaging: recommendations from the National Cancer Imaging Translational Accelerator (NCITA) consensus meeting.

McAteer M, McGowan D, Cook G, Leung H, Ng T, OConnor J BMC Med. 2025; 23(1):37.

PMID: 39849494 PMC: 11756105. DOI: 10.1186/s12916-024-03831-z.

F-FET PET/CT can aid in diagnosing patients with indeterminate MRI findings for brain tumors: a prospective study.

Chan S, Chiu T, Ng S, Kao H, Tsai S, Liu S Ann Nucl Med. 2024; .

PMID: 39589672 DOI: 10.1007/s12149-024-02005-4.

Complex Diagnostic Challenges in Glioblastoma: The Role of F-FDOPA PET Imaging.

Sipos D, Debreczeni-Mate Z, Ritter Z, Freihat O, Simon M, Kovacs A Pharmaceuticals (Basel). 2024; 17(9).

PMID: 39338377 PMC: 11434841. DOI: 10.3390/ph17091215.

ASL, DSC, DCE perfusion MRI and 18F-DOPA PET/CT in differentiating glioma recurrence from post-treatment changes.

Moltoni G, Romano A, Capriotti G, Campagna G, Ascolese A, Romano A Radiol Med. 2024; 129(9):1382-1393.

PMID: 39117936 PMC: 11379733. DOI: 10.1007/s11547-024-01862-3.

References

Becherer A, Karanikas G, Szabo M, Zettinig G, Asenbaum S, Marosi C . Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging. 2003; 30(11):1561-7. DOI: 10.1007/s00259-003-1259-1. View

Deeks J, Macaskill P, Irwig L . The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005; 58(9):882-93. DOI: 10.1016/j.jclinepi.2005.01.016. View

Chen W, Silverman D, Delaloye S, Czernin J, Kamdar N, Pope W . 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006; 47(6):904-11. View

Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A . Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006; 6:31. PMC: 1552081. DOI: 10.1186/1471-2288-6-31. View

Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View

Tripathi M, Sharma R, Dsouza M, Jaimini A, Panwar P, Varshney R . Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas. Clin Nucl Med. 2010; 34(12):878-83. DOI: 10.1097/RLU.0b013e3181becfe0. View

Dhermain F, Hau P, Lanfermann H, Jacobs A, van den Bent M . Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 2010; 9(9):906-20. DOI: 10.1016/S1474-4422(10)70181-2. View

Fueger B, Czernin J, Cloughesy T, Silverman D, Geist C, Walter M . Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med. 2010; 51(10):1532-8. DOI: 10.2967/jnumed.110.078592. View

Fougere C, Suchorska B, Bartenstein P, Kreth F, Tonn J . Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol. 2011; 13(8):806-19. PMC: 3145468. DOI: 10.1093/neuonc/nor054. View

10.

Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J . QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155(8):529-36. DOI: 10.7326/0003-4819-155-8-201110180-00009. View

11.

Jora C, Mattakarottu J, Aniruddha P, Mudalsha R, Singh D, Pathak H . Comparative evaluation of 18F-FDOPA, 13N-AMMONIA, 18F-FDG PET/CT and MRI in primary brain tumors - A pilot study. Indian J Nucl Med. 2011; 26(2):78-81. PMC: 3237222. DOI: 10.4103/0972-3919.90256. View

12.

Dunet V, Rossier C, Buck A, Stupp R, Prior J . Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. J Nucl Med. 2012; 53(2):207-14. DOI: 10.2967/jnumed.111.096859. View

13.

Youland R, Kitange G, Peterson T, Pafundi D, Ramiscal J, Pokorny J . The role of LAT1 in (18)F-DOPA uptake in malignant gliomas. J Neurooncol. 2012; 111(1):11-8. PMC: 3907171. DOI: 10.1007/s11060-012-0986-1. View

14.

Nioche C, Soret M, Gontier E, Lahutte M, Dutertre G, Dulou R . Evaluation of quantitative criteria for glioma grading with static and dynamic 18F-FDopa PET/CT. Clin Nucl Med. 2013; 38(2):81-7. DOI: 10.1097/RLU.0b013e318279fd5a. View

15.

Pafundi D, Laack N, Youland R, Parney I, Lowe V, Giannini C . Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol. 2013; 15(8):1058-67. PMC: 3714146. DOI: 10.1093/neuonc/not002. View

16.

Karunanithi S, Bandopadhyaya G, Sharma P, Kumar A, Singla S, Malhotra A . Prospective comparison of (99m)Tc-GH SPECT/CT and (18)F-FDOPA PET/CT for detection of recurrent glioma: a pilot study. Clin Nucl Med. 2013; 39(2):e121-8. DOI: 10.1097/RLU.0b013e318279bcd8. View

17.

Karunanithi S, Sharma P, Kumar A, Khangembam B, Bandopadhyaya G, Kumar R . Comparative diagnostic accuracy of contrast-enhanced MRI and (18)F-FDOPA PET-CT in recurrent glioma. Eur Radiol. 2013; 23(9):2628-35. DOI: 10.1007/s00330-013-2838-6. View

18.

Omuro A, DeAngelis L . Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013; 310(17):1842-50. DOI: 10.1001/jama.2013.280319. View

19.

Herrmann K, Czernin J, Cloughesy T, Lai A, Pomykala K, Benz M . Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. Neuro Oncol. 2013; 16(4):603-9. PMC: 3956344. DOI: 10.1093/neuonc/not166. View

20.

Lapa C, Linsenmann T, Monoranu C, Samnick S, Buck A, Bluemel C . Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients. J Nucl Med. 2014; 55(10):1611-6. DOI: 10.2967/jnumed.114.140608. View